Background: The current study evaluated the level of serum N1-methylnicotinamide (me-NAM) in cervical cancer patients and further explored whether serum me-NAM was related to the prognosis of cervical cancer.
Methods: Fifty-eight cases of cervical intraepithelial neoplasia patients, 78 cases of cervical cancer patients, and 52 healthy women were included in the present study. Serum me-NAM concentrations were determined by liquid chromatography with tandem mass spectrometry. Receiver operating characteristic (ROC) curve was used to assess me-NAM as a biomarker and Kaplan-Meier analysis was carried out to evaluate the survival rate.
Results: Our data showed that the level of serum me-NAM in cervical cancer patients was significantly higher than that in the cervical intraepithelial neoplasia group and the healthy control group. Furthermore, the level of me-NAM in cervical cancer tissues of stage I, II, III, and IV was higher than that of those without lymph node metastasis. The area under the receiver operating characteristic curve (ROC) for me-NAM was higher than that of squamous cell carcinoma antigen (SCC Ag) and carbohydrate antigen 125 (CA125) when comparing cervical cancer from CIN or healthy control. The combination of me-NAM and SCC Ag or CA125 could improve the diagnostic efficiency better than SCC Ag or CA125 alone. Compared with me-NAM low expression group, the survival rate and time of me-NAM high expression group were lower and shorter.
Conclusions: Altogether, elevated serum me-NAM levels contribute to the progression of cervical cancer and may be used as a marker for the prognosis of patients with cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7754/Clin.Lab.2020.200422 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings.
J Clin Microbiol
December 2024
National Cancer Institute, Rockville, Maryland, USA.
Unlabelled: Human papillomavirus (HPV) genotype predicts cervical cancer risk, and genotyping could help guide the management of HPV positives as part of cervical screening. An isothermal amplification HPV extended genotyping test (ScreenFire HPV RS assay) can assay up to 96 samples/controls in 1 hour plus preparation time. A novel format with pre-aliquoted reagents and an anti-contamination component (Zebra BioDome) could simplify the HPV testing process and reduce the chances of post-amplification contamination.
View Article and Find Full Text PDFHigh rate of persistent HPV detection after diagnostic cervical excision in older screen-positive women.
Acta Obstet Gynecol Scand
January 2025
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Introduction: Diagnostic work-up of older women with a positive cervical cancer screening test is often challenging due to incomplete visualization of the transformation zone. To reduce the risk of missing disease, a diagnostic cervical excision may be performed. However, little is known on treatment efficacy and post-treatment surveillance for older women.
View Article and Find Full Text PDFRosai-Dorfman Disease Presenting With FDG-Avid Breast Masses and Axillary Lymph Nodes on PET-CT in a Patient With Recent Diagnosis of Endometrial Carcinoma: A Diagnostic Dilemma.
Eur J Breast Health
January 2025
Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Rosai-Dorfman disease (RDD) is a self-limited, idiopathic, non-neoplastic disorder characterized by the proliferation of phagocytic histiocytes, which can mimic malignant lymphoproliferative disease. Cases of RDD most commonly present as bilateral painless cervical lymphadenopathy, with lesser involvement of the axilla, inguinal, and mediastinal lymph nodes. We present the case of a 62-year-old woman with a history of endometrial serous carcinoma who underwent evaluation at a dedicated breast imaging department after positron emission tomography/computed tomography (PET/CT) revealed breast masses and axillary nodes with increased uptake of fluorodeoxyglucose (FDG).
View Article and Find Full Text PDFBioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: Genes Address Common Hub Genes and Drugs.
Eur J Breast Health
January 2025
Department of Biomedical Engineering, Faculty of Engineering, İzmir University of Economics, İzmir, Turkey.
Objective: The prevalence of breast cancer and gynaecological cancers is high, and these cancer types can occur consecutively as secondary cancers. The aim of our study is to determine the genes commonly expressed in these cancers and to identify the common hub genes and drug components.
Materials And Methods: Gene intensity values of breast cancer, gynaecological cancers such as cervical, ovarian and endometrial cancers were used from the Gene Expression Omnibus database Affymetrix Human Genome U133 Plus 2.
Screening of Hub Genes and Therapeutic Drugs in Cervical Cancer Using Integrated Bioinformatics Analysis.
J Cancer
January 2025
Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Xinjiang, China.
Cervical cancer (CC) is one of the most common female malignancies globally. The current study aimed to identify novel hub genes associated with traditional Chinese herbs and investigate their underlying mechanisms using bioinformatics analysis combined with experimental verification. Expression profiling of 22 samples was obtained from the GEO database.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!